SBIOClinical•globenewswire•
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
Sentiment:Neutral (45)
Summary
- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 -
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire